| Overview |
| bsm-52672r-100ul |
| RUNX2 Recombinant Antibody |
| WB, Flow-Cyt, ICC/IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Human RUNX2 between 300 to 450 amino acids |
| 300-450/521 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 860 |
| Q13950 |
| Runt-related transcription factor 2, Acute myeloid leukemia 3 protein, Core-binding factor subunit alpha-1, Oncogene AML-3, Osteoblast-specific transcription factor 2, Polyomavirus enhancer-binding protein 2 alpha A subunit, SL3-3 enhancer factor 1 alpha A subunit, SL3/AKV core-binding factor alpha A subunit, CBF-alpha-1, OSF-2, PEA2-alpha A, PEBP2-alpha A, RUNX2 |
| Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. |
| Application Dilution |
| WB |
1:300-5000 |
| Flow-Cyt |
1ug/Test |
| ICC/IF |
1:50-100 |
Powered by Bioz